Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Opdivo
Pharma
FDA challenges broad use of PD-1 drugs in stomach cancer
The FDA is considering a class-wide action against PD-1 inhibitors in stomach cancer and esophageal cancer based on findings from multiple trials.
Angus Liu
Sep 24, 2024 2:30pm
ESMO: GSK's Zejula, pharma&'s Rubraca-Opdivo combo disappoint
Sep 14, 2024 8:45am
With ODAC, FDA weighs limiting PD-1 drugs in stomach cancer
Aug 22, 2024 3:28pm
Amid concerns, FDA approves AZ's Imfinizi in perioperative NSCLC
Aug 16, 2024 10:51am
FDA's ODAC calls for revamp of perioperative NSCLC trials
Jul 25, 2024 5:00pm
AZ set to face tough questions on Imfinzi expansion bid in NSCLC
Jul 24, 2024 8:29am
